Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TILs + Pembrolizumab in Metastatic Cancers
NCT01174121Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2010
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous tumor-infiltrating lymphocytes and pembrolizumab in metastatic colorectal cancer (mCRC), Malignant ovarian neoplasm (OC), breast cancer and 2 more (5 arms), sponsored by National Cancer Institute. Primary endpoint: Response rate at 24 months. Started Aug 2010; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytespembrolizumab
03
Conditions
metastatic colorectal cancer (mCRC)Malignant ovarian neoplasm (OC)breast cancerEndocrine gland neoplasm (EGN)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT01174121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01174121.